Cost-Effectiveness Analysis Of Regorafenib In Gastrointestinal Stromal Tumours In England Using Crossover Adjustment Methods

A placebo-controlled randomised trial (GRID) compared regorafenib and best supportive care (BSC) to BSC alone in the treatment of metastatic/unresectable gastrointestinal stromal tumours in patients previously treated with imatinib and sunitinib. Regorafenib significantly improved progression-free survival; however, overall survival (OS) did not differ significantly between arms. By 8th June 2015, 87.9% of BSC patients switched to regorafenib post-progression; switching occurred at a median of 0.9 months after randomisation.
Source: Value in Health - Category: Global & Universal Authors: Source Type: research